We are committed to serving the best interests of our shareholders. If you require assistance or have questions regarding the key shareholder information and financial reports available here please contact us.
Jun 28, 2016
Cascadian Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of $46.0 million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock
Jun 14, 2016 at 2:00 PM ET
Cascadian Therapeutics R&D Day